Daily

Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine

- Article Discussing Pharmacokinetics and Dose Proportionality ofCompany's Once-Daily Tramadol to be Published in BiopharmaceuticsJournal - LAVAL, QC, June 29, 2007 /PRNewswire-FirstCall/ - Labopharm Inc.today announced that it will present a poster discussing the dosetitration of its once-daily formulation of tramadol at the 3rdInternational Forum on Pain Medicine to be held June 28 to J...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen InInsulin Therapy CHICAGO, June 24, 2007 – Novo Nordisk today announcedresults of a new study that further demonstrated the safety andefficacy of insulin Levemir® (insulin detemir [rDNA origin]injection). Patients with Type 2 diabetes were able to adjusttheir own dosage of Levemir® and achieve improvements i...

Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target

New study demonstrates 75% of patients receiving highest doseachieves A1c with no associated hypoglycemia CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- According tofindings presented today at the 67th Scientific Sessions of theAmerican Diabetes Association (ADA) in Chicago, Illinois, theinvestigational treatment liraglutide, a once- daily dose of humanGLP-1 analog under development by...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen InInsulin Therapy CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Novo Nordisktoday announced results of a new study that further demonstratedthe safety and efficacy of insulin Levemir(R) (insulin detemir[rDNA origin] injection). Patients with type 2 diabetes were ableto adjust their own dosage of Levemir(R) and achieve improvem...

International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinson's Disease

Results presented at the Movement Disorder Society's 11thInternational Congress in Istanbul, Turkey KANSAS CITY, Mo., June 08, 2007 /PRNewswire-FirstCall/ -- Newinformation on the use of AZILECT(R) (rasagiline tablets) for thetreatment of Parkinson's disease (PD) was reported this week at TheMovement Disorder Society's congress in Istanbul, Turkey.Once-daily AZILECT was approved by the FD...

New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia

--Study Used To Support FDA Approval of SEROQUEL XR-- WILMINGTON, Del., May 22, 2007 /PRNewswire-FirstCall/ --AstraZeneca today announced that two analyses from a large-scalestudy that investigated the efficacy of SEROQUEL XR(TM) (quetiapinefumarate) Extended-Release Tablets, a once-daily medicine for thetreatment of schizophrenia in adult patients, were presented todayat the annual meeti...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life

UC's Overall Psychological Toll Is Greater Than for Asthma,Rheumatoid Arthritis and Migraines WAYNE, Pa., May 17, 2007 /PRNewswire/ -- Nearly three out offour ulcerative colitis (UC) sufferers (73 percent) responding to anew nationwide survey say not feeling well has become a normal partof life. Furthermore, they describe UC as disruptive when it comesto their relationship with a spouse (...

Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory Dose Doxycycline for the Treatment of Rosacea

NEWTOWN, Pa.--(BUSINESS WIRE)--Apr 30, 2007 - CollaGenexPharmaceuticals, Inc. (NASDAQ:CGPI) today announced that a newreport in the May 2007 issue of the Journal of the American Academyof Dermatology evaluating two randomized phase III clinical trials,demonstrated the efficacy and safety of anti-inflammatory dosedoxycycline (Oracea(R), 40-mg doxycycline, USP capsules) for thetreatment of ro...

Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa

'Off' Time Reduced By an Average of More Than Two Hours Per Day RESEARCH TRIANGLE PARK, N.C., April 02, 2007 /PRNewswire/ --Adding the once daily, investigational medication REQUIP(R)(ropinirole HCl) XL 24-Hour(TM) Extended-Release Tablets toParkinson's patients' existing levodopa (L-dopa) therapysignificantly reduced 'off' time, allowing patients to continuetheir daily activities for a l...